Leaving UL Solutions website
Within UL Solutions we provide a broad portfolio of offerings to all the medical device industries. This includes certification, Approved/Notified Body and consultancy services. In order to protect and prevent any conflict of interest, perception of conflict of interest and protection of both our brand and our customers brand, we have processes in place to identify and manage any potential conflicts of interest and maintain impartiality. UL Solutions is unable to provide consultancy services to EU MDD, MDR or IVDD Notified Body, UKCA MD Approved Body or MDSAP Customers.
  • Feature Story

U.S. District of Columbia Enacts Carcinogenic Flame Retardant Prohibition Amendment Act of 2016

Contact UL

May 13, 2016

Beginning January 1, 2018, no person or legal entity shall manufacture, sell, offer for sale, or distribute any children's product or residential upholstered furniture in Washington, D.C., containing more than 0.1 % by mass in any product component of the following:

  • Tris(l,3-dichloro-2-propyl) phosphate (TDCPP)
  • Tris(2-chloroethyl) phosphate (TCEP)

Beginning January 1, 2019, no person or legal entity shall manufacture, sell, offer for sale, or distribute any product in Washington, D.C. containing more than 0.1 % by mass in any product component of the following:

  • Tris(l,3-dichloro-2-propyl) phosphate (TDCPP)
  • Tris(2-chloroethyl) phosphate (TCEP)

An exemption applies to retailers who purchased or acquired the product before the effective date of the Carcinogenic Flame Retardant Prohibition Amendment Act of 2016, passed on March 1, 2016.

Source